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Abstract
Cerebrovascular diseases (cerebral infarction, intracranial haemorrhage and vasculop‐
athy) are common manifestations of sickle cell disease (SCD) associated with significant
morbidity and mortality. These neurological complications and potential corresponding
neuropsychological compromise may have devastating consequences for a child with
SCD. This chapter aims to review the neurological complications in SCD using magnetic
resonance imaging (MRI) as both a qualitative and a quantitative tool for detecting
abnormality. Advanced MRI pulse sequences, such as high‐resolution 3D T1‐weighted
imaging for brain volumetrics, diffusion tensor imaging for white matter integrity and
non‐invasive perfusion MRI for cerebral blood flow (CBF) measurement, can provide
additional information about the structure and function of brain tissue beyond the scope
of  conventional  clinical  imaging.  These  studies  have  set  to  establish  quantitative
biomarkers that relate to disease severity and neuropsychological sequelae.
Keywords: sickle cell anaemia, MRI, cerebrovascular disease, stroke, neuropsycholo‐
gy
1. Introduction
Sickle cell disease (SCD) is the commonest cause of stroke in childhood [1, 2]. Focal cerebral
ischaemia due to arterial or venous compromise is rarely fatal but accounts for 70–80% of all
strokes [3–5] and nearly all episodes in children younger than 15 and adults older than 30
years. Subarachnoid and intracerebral haemorrhage typically occurs between 20 and 30 years
of age and has a high mortality [4, 6, 7]. Without preventative strategies, approximately 11%
of patients with genotype HbSS will experience a clinically apparent stroke by age 20 and up
to  24% by  age  45  [6].  Silent  cerebral  infarction  (SCI)  is  diagnosed only  using  magnetic
resonance imaging (MRI) in patients with no focal neurological deficit, but is associated with
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cognitive difficulties [8] that families often report. SCI can develop very early in life, with rates
between 11 and 15% in children less than 2 years [9–11] and progressive accrual throughout
childhood and adolescence [11, 12] and into adulthood.
2. Pathophysiology of cerebrovascular ischaemic events
Clinical stroke is defined as a focal neurological event lasting more than 24 hours and is usually
permanent, whereas transient ischaemic events are focal neurological events lasting less than
24 hours (i.e. there is a full clinical recovery) [13]. Reversible ischaemic neurological deficits
last more than 24 hours, but recover fully. None of these clinical definitions require neuroi‐
maging confirmation, although episodes lasting less than 24 hours but accompanied by an
acute infarct in the corresponding territory should be considered as strokes. People with HbSS
and HbSβ0‐thalassaemia genotypes are at highest risk, although stroke has been documented
in children with HbSS and HbSβ+‐thalassaemia genotypes [6]. Stroke can occur as early as 6–
12 months [14] when HbF decreases and HbS begins to be synthesised; the first decade of life,
when the onset of strokes typically occurs, appears to constitute a ‘critical period’ for neuro‐
logic complications and subsequent neurocognitive morbidity [6, 15].
Overt stroke is usually associated with large vessel arterial disease, with evidence of stenosis
in the internal carotid artery distribution [16], and pathologies are frequently seen in brain
tissue within the anterior cerebral and middle cerebral artery territories [17–19]. Transcranial
Doppler (TCD) may be used to screen for high cerebral blood flow (CBF) velocities consistent
with stenosis or hyperaemia; although conventional angiography is rarely justified, magnetic
resonance angiography may confirm focal stenosis but is not essential for management.
Risk factors for cerebral infarction include classical risk factors as in the general population:
hypertension [6, 20], presence of a prior cerebral infarct [3, 21], acute low oxygen delivery
associated with lower oxygen saturation [22, 23], acute drop in haemoglobin [24] and presence
of cerebral vasculopathy [18, 25] compromising cerebral blood flow (CBF). Increased CBF
velocity, in response to anaemia, results in adaptive vasodilation of vessels to match metabolic
demand, reducing cerebrovascular reserve [26] and causing injury to the endothelial cells
lining the vascular wall [5, 27]. Any further demand when metabolic rate is high (e.g. secondary
to fever or seizures) or when there is an acute drop in oxygen delivery could cause large and
small vessel injury/ischaemia [28], especially in ‘borderzones’, where blood flow may be
lower [29] in the context of large vessel disease and relative hypotension [30].
More common than overt stroke, up to 35% of children will show evidence of SCI [31],
diagnosed using MRI as a lesion seen in two planes of a scan with no history of stroke [9, 30,
32, 33]. In children with evidence of SCI on MRI, there is a 14‐fold increase in the risk of clinical
stroke [34] and further SCI [16]. Known risk factors for SCI are lower rate for pain crises, history
of seizures, increased leukocyte count and Senegal beta‐globin haplotype [35], but also low
baseline haemoglobin [36], male sex and higher baseline systolic blood pressure [37]. The
presence of acute silent cerebral infarction events (ASCIE), seen as lesions on imaging which
may or may not progress to SCI, has been shown to be temporally associated with clinical
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events [38]. SCI by definition are clinically silent, so timing is unknown; however, it has been
postulated that these lesions are the result of recurrent micro‐infarctions and recurrent acute
hypoxic damage [24, 39, 40] secondary to severe anaemia, diminished pulmonary function,
splenic sequestration, aplastic crisis and acute chest syndrome [41, 42].
3. Primary and secondary stroke prevention
In children, transcranial Doppler (TCD) ultrasound screening to measure blood flow velocity
in the intracranial vessels has become an established and effective method of primary stroke
prevention. Three groups have been identified with increasing risk of stroke: normal TCD
velocities (<170cm/s), conditional TCD velocities (170–200cm/s) and abnormal velocities
(>200cm/s) [43]. The Stroke Prevention (STOP) trial randomised children with abnormal TCD
velocities (>200 cm/s) to regular transfusion and was discontinued early as an interim analysis
showed that there was a 92% reduction in the risk stroke in the transfused arm [44, 45]. The
US National Heart, Lung, and Blood Institute and UK National Health Service recommend all
children should have TCD screening and be transfused if their velocities are greater than
200cm/s [46]. Current guidelines state that those children should be transfused indefinitely
[47], but the TCD with transfusions changing to hydroxyurea (TWiTCH) trial suggests that,
for those with no MRA abnormality may be able to switch to hydroxyurea prophylaxis after
a year of transfusion [48]. Hydroxyurea does appear to reduce TCD velocities even without
prior blood transfusion [1]; so, in settings where TCD is available but blood transfusion is not
possible or is considered hazardous, it is probably reasonable to start hydroxyurea while the
results of controlled trials are awaited [49]. In adults with SCD, there are no validated methods
to screen for the increased stroke risk, as TCD studies in adults with HbSS find lower velocities
than in children and cannot accurately stratify the risk of stroke [50].
For secondary stroke prevention, it is important to know the nature of the primary event and
any associated arterial or venous abnormality as well as the setting (e.g. ‘out‐of‐the‐blue’ or in
the context of acute chest or painful crisis), as estimating recurrence risk depends on these
variables [21, 51]. While chronic transfusion for secondary stroke prevention is common
practice, it may not fully prevent recurrent stroke [21, 51, 52] and is associated with antibody
development, iron overload and significant cost. Other treatments such as hydroxyurea for
primary [53] and secondary stroke prevention [54, 55] have been showing promise.
4. Sickle cell neuroradiology
In clinical settings after an acute event (e.g. hemiplegia, seizures or acute coma), MRI and MRA
protocols usually consist of T2‐weighted or fluid-attenuated inversion recovery (FLAIR)
sequences in the axial and coronal planes, a coronal T1‐weighted image, diffusion-weighted
images and time-of-flight MR angiography protocols to show intravascular appearances.
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4.1. MRA findings
MRA studies confirm pattern of occlusion/stenosis from vessels of the internal carotid
distribution with relative sparing of the posterior circulation [56]; stroke and SCI from
vertebrobasilar artery circulation occlusion are less common, but have been reported [56, 57].
Approximately 10% of children have cerebral vasculopathy [58, 59] and/or moyamoya
syndrome [25], which may be asymptomatic with SCI seen on MRI [59] but renders the child
at significant risk of stroke [25].
4.2. MRI findings
4.2.1. Definition of SCI
Although stroke is identified by abrupt onset of neurological deficit and does not require
neuroimaging evidence, the term ‘covert stroke’ [60], or SCI, was first described in the
Cooperative Study in Sickle Cell Disease (CSSCD) [32] and requires both a neuroimaging
definition. SCI is described for the silent infarct transfusion (SIT) trial [37, 61] as an MRI lesion
measuring at least 3 mm in greatest linear dimension, visible in two planes of T2‐weighted
images (axial and coronal), and a neurology definition of a normal neurologic exam or an
abnormal exam that could not be explained by the location of the brain lesion [62]. Many
studies describe a localisation of SCI to deep white matter (Figure 1), particularly in the arterial
borderzones [11, 42, 57, 63, 64]. Infarcts in the subcortical grey matter structures (i.e. head of
caudate, cerebellum) are less common [57, 63].
Figure 1. An example of SCI in a 12‐year‐old boy with HbSS.
4.2.2. Progression of SCI
Several longitudinal studies have shown the presence of SCI as a risk factor for clinical stroke
and further SCI. In the CSSCD study, approximately 25% of the children with SCI, but only
2.5% of the children without SCI, had new and/or enlarging lesions on follow‐up MRI scan
[30], predicting a 14‐fold higher risk for clinical stroke and further SCI [65].
SCI have been reported in very young children; 4/39 children (10%) with SCA and no history
of stroke between 7 and 48 months of age had SCI [9]; 3/23 children (13%) at an average age of
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13.7 months had SCI [10]; and 18/65 children (27.7%) with SCA who were asymptomatic had
SCI [31]. A French study showed incidence of SCI as 28.2% by 8 years and 37.4% by 14 years
[66]. Although it was thought that rates plateau in childhood, there is now evidence of new
SCI in older adolescence and adulthood [1, 67]. In the London cohort followed from the
mid‐1990s [68], 30% (3/10 patients) were found to have new SCI after the age of 14, 17 and 21
years, respectively (Figures 2 and 3).
Figure 2. Serial imaging of a male with HbSS. Patient was 17 years old on T2‐weighted image from 2001 (left)—show‐
ing a small right frontal SCI. Patient was 28 years old on T2‐weighted image from 2013 (right)—showing no progres‐
sion in size of original right frontal SCI but evidence of new SCI in the right peritrigonal region.
Figure 3. Serial imaging of a male with HbSS. Patient was 14 years old on T2‐weighted image from 2002 (top panel)—
showing a small left peritrigonal SCI. Patient was 26 years old on T2‐weighted image from 2013 (bottom panel)—show‐
ing no progression in size of original SCI, but evidence of new SCI in both cerebellar hemispheres.
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The SIT trial showed that in children aged 5–14 years with SCI, regular blood transfusion
reduced the risk of reinfarction, both overt (clinical stroke) and silent [62]. Preliminary
observational data from the Hydroxyurea Study of Long‐Term Effects (HUSTLE‐
NCT00305175) study suggest that progressive SCI are less likely to accumulate in children
taking hydroxyurea to maximum tolerated dose [69], but no randomised controlled trials are
available yet.
4.2.3. Acute silent cerebral ischemic events (ASCIE)
It has been argued that categorically dividing ischaemic events between clinical stroke
and SCI may be an oversimplification of the spectrum of brain injury in SCD [38]. ASCIE
[38, 40], following acute severe anaemia [24, 35, 70, 71], can be detectable in the first few
days after the clinical event using diffusion-weighted imaging (DWI), in which the ‘appa‐
rent’ diffusion coefficient (ADC) is measured within each voxel and representing an index
of the mobility of water molecules inside biological tissues. In acute ischaemia, an area of
oedema in the brain has a rapid decline in proton density and appears hyperintense on
DWI and decreased on an ADC map, persisting for 10–14 days post‐event [72], which can
differentiate acute stroke from more remote events [24]. Not all children with evidence of
ASCIE progress to SCI on MRI [1, 62], which strongly suggests acute ischaemia may be
reversible.
4.2.4. Other acute pathologies on MRI
Imaging abnormality in the occipito‐parietal or thalamic region suggests cerebral venous
sinus thrombosis but there may be no parenchymal change and this diagnosis should al‐
ways be excluded with a venogram in patients with SCD presenting in coma or with seiz‐
ures or acute psychiatric symptoms as well as focal neurology [73]. Subarachnoid and
intracerebral haemorrhage also occur [74], as a result of sinovenous thrombosis, rupture of
aneurysms (usually located at the bifurcations of major vessels, particularly in the vertebro‐
basilar circulation) [75], or of fragile moyamoya vessels. Risk factors include recent trauma,
transfusion in the past fortnight, corticosteroid or non‐steroidal anti-inflammatory use and
intermittent hypertension [76]. Posterior reversible encephalopathy syndrome (Figure 4,
left) has also been reported in the context of hypertension and cyclosporine use for neph‐
rotic syndrome [77], as well as after acute chest syndrome [78, 79]. Acute bilateral border‐
zone ischaemia may also occur secondary to inadequate global CBF to supply the tissue’s
demand for oxygen (e.g. during acute chest crisis or seizures; Figure 4, middle, right).
Management along the lines of the current guidelines for the diagnosed condition in the
general paediatric population should be considered, e.g. acute anticoagulation with hepa‐
rin for cerebral venous sinus thrombosis, neurosurgery for drainage of haematoma and
surgery or interventional neuroradiology for removal of aneurysm after intracranial hae‐
morrhage, and steady slow reduction of any associated high blood pressure associated
with PRES [80, 81].
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Figure 4. Left: Signal change in the grey and white matter (arrows; posterior reversible encephalopathy syndrome) in a
9‐year‐old boy with HbSS and nephrotic syndrome who had seizures after cyclosporin therapy. Middle: Bilateral bor‐
derzone ischaemia in a 25‐year‐old woman with HbSS who collapsed with seizures soon after discharge after acute
chest crisis. Right: Infarction in both anterior and posterior borderzones in an 8‐year‐old boy with previously uncom‐
plicated sickle cell anaemia who developed seizures and coma after surgery to drain a painful swelling of his left cheek
associated with fever.
5. Quantitative MRI findings: cross-sectional and longitudinal case control
studies
Since the 1990s when MRI was used routinely in clinical practice, vast improvements in MRI
hardware, software, sequence design and processing techniques have allowed for quantitative
measurement of neurological abnormality in SCD. Beyond conventional MRI protocols for
acute CNS event detection, only in the last 10–15 years advanced MRI sequences for quanti‐
tative analyses have been published, providing further insight into the pathophysiology and
progression of neurological complications.
5.1. Morphometric studies using T1-weighted MRI
High‐resolution T1‐weighted data, with good contrast between grey and white matter, can
give valuable insight into volumetrics of the brain. An earlier report showed significant
reduction in total subcortical grey matter volume (i.e. basal ganglia volume) as compared to
cortical grey matter volume [82]. Decrease in volume of specific subcortical structures (e.g.
hippocampus, amygdala, globus pallidus, caudate and putamen) follows parallel to increasing
burden of SCI: those with evidence of SCI in white matter have decreased volumes of deep
grey matter structures compared to those without SCI and controls [83].
Morphometric studies give a quantitative approach to brain tissue volumes. In a surface‐based
morphometric study, older children without SCI showed significant thinning of cortex
compared to younger patients in the posterior medial surfaces of both hemispheres [84]. A
whole‐brain voxel‐based morphometry (VBM) study found in children without evidence of
SCI, decreased grey matter volume in bilateral frontal, temporal and parietal lobes was found
to correlate with low IQ [85]. Also using VBM, Baldeweg et al. [86] found that in a group with
existing SCI, there were significant decreases in white matter density extending bilaterally from
the anterior frontal lobes along the ventricles to parieto‐occipital lobes, as well as along the
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corpus callosum. In those without evidence of SCI, smaller but similar significant decreases in
white matter density were found, suggesting patients may have compromised white matter
even with normal conventional imaging (Figure 5). The only longitudinal morphometric study
to date has found different trajectories for brain tissue growth during childhood, with a
significant decline in total grey matter volume distributed broadly across the brain compared
to healthy controls (HC) [87].
Figure 5. Voxel‐based morphometry study showing decreased white matter density extending bilaterally from the an‐
terior frontal lobes along the ventricles to parieto‐occipital lobes (image taken with permission from Baldeweg et al.
[86]).
5.2. Diffusion tensor imaging
Diffusion tensor imaging (DTI) relies on the properties of the diffusion of water molecules to
show directionality (anisotropy) of the underlying tissue. Anisotropy can be quantified by
measuring at least six directions [88], unlike ADC maps from DWI data that only require three
directions, by a diffusion tensor, a mathematical model usually visualised as an ellipsoid
(Figure 6). From the diffusion tensor model, several quantitative metrics can be calculated:
fractional anisotropy (FA), or the degree of anisotropy ranging from 0 to 1 representing the
coherence, organisation and/or density of the underlying tissue, and mean diffusivity (MD),
or the average water molecular displacement which is equivalent to ADC. MD can also be
divided into axial diffusivity (AD), the magnitude of diffusion along the principal direction of
diffusion, and radial diffusivity (RD), or the average magnitude of diffusion along the two
perpendicular directions of diffusion. These metrics may provide additional information
related to demyelination [89] and axonal damage [90]. There are two main approaches to
analyse diffusion data: a voxel‐based approach using regions‐of‐interest (ROIs) or whole‐brain
data, or tractography (Figure 6), where reconstruction of major white matter tracts can be
performed by following the continuity and direction of maximum diffusion from contigu‐
ous voxels [91].
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Figure 6. Diffusion tensor imaging. (1) The diffusion tensor model showing ellipsoids representing voxel with isotropic
diffusion (top) and anisotropic diffusion (bottom). (2) Diffusivity maps showing (a) mean diffusivity (b) axial diffusivi-
ty and (c) radial diffusivity. (3) (a) Fractional anisotropy maps with (b) directions of principal diffusion overlaid (c)
tractography of anterior corpus callosum overlaid.
A DWI study showed significant increases in mean regional ADC of patients relative to
controls in six large ROIs (left and right frontal lobe, left and right cerebellum, pons and
vermis), and in patients with no evidence of infarct, there was increased ADC in four regions
(excluding pons and vermis) [92]. These widespread differences in diffusion have been
confirmed by DTI studies. In a combined ROI and tractography study of 16 patients with SCD
aged 16–45, reduced FA was found in the corpus callosum, centrum semiovale, periventricular
areas and ROIs in the subcortical white matter. Tractography of the corpus callosum showed
reduced fibre count (i.e. streamlines) and reduced FA in the anterior body [93]. Two studies
have used a whole‐brain analysis technique known as tract‐based spatial statistics (TBSS) [94],
in which a ‘skeleton’ of white matter is investigated to reduce partial volume effects. In a study
of two groups of children with SCA, some of whom had mild gliosis although none had SCI,
patients with mild gliosis had increased diffusivity and reduced FA in the body of the corpus
callosum, whereas the no‐SCI group had reduced FA in the centrum semiovale compared to
controls [95]. Another TBSS study in 25 patients with no evidence of SCI showed FA signifi-
cantly lower in cerebral peduncles and cerebellar white matter, whereas there were widespread
increases in MD and RD across frontal and parietal lobes, corpus callosum and subcortical
white matter. Furthermore, significant negative correlations were found between daytime
peripheral oxygen saturation (SpO2) and haemoglobin and RD in the anterior corpus callosum
[96] (Figure 7).
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Figure 7. Results from a recent DTI‐TBSS study [96], showing the white matter ‘skeleton’ (green) and significant corre‐
lations between RD and daytime peripheral oxygen saturation (blue) and haemoglobin (red).
5.3. Perfusion MRI
Perfusion MRI, either through traditional imaging after injection of a paramagnetic contrast
agent (e.g. Gadolinium) or non‐invasive arterial‐spin labelling (ASL) techniques, has the
longest history in quantitative MRI in SCD. In patients with chronic cerebrovascular pathology
and stroke, dynamic susceptibility contrast MRI (DSC‐MRI) has shown focal areas of reduced
CBF and prolonged mean transit time in the affected corresponding to stroke‐like lesions [29,
97]. Studies have consistently shown elevated global cerebral blood flow (CBF) [98–104], in
association with the elevated cerebral blood flow velocity [28], which may be both a response
to and a risk factor for cerebral hypoxia [98, 99] and related to low haematocrit [98] and
haemoglobin and haemoglobin F [103]. Strouse et al. [99] found a strong inverse correlation
with CBF and both full‐scale IQ and performance IQ, which may be more sensitive than CBF
velocity measured by TCD [105].
ASL protocols have become more popular as they do not require intravenous injection;
however, they have widely differed in acquisition, CBF quantification and arterial territory
segmentation techniques [103], leading to discrepancies in interpretation. CBF quantification
depends on the T1 value of blood, which is assumed in some studies [99, 101] but might be
more accurate if it were corrected for haematocrit [100]. An ASL acquisition with multiple
inflow times [106] does not require prior assumptions about the necessary delay for the fully
labelled bolus of blood to arrive and may characterise the full haemodynamic behaviour within
a voxel. Unpublished data from a London cohort (n=39 patients) with multiple inflow time
data confirms global elevated CBF compared to a previously published reference range for
healthy children [1]. This study also shows significant correlations with oxygen saturation and
haematocrit with CBF in the anterior, middle and posterior cerebral arteries.
5.3.1. Combined diffusion and perfusion studies
Kirkham et al. [29] found perfusion/diffusion mismatch in areas seen as normal on T2‐
weighted images, suggesting CBF was reduced but not enough for cytotoxic oedema and tissue
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death. Similarly, a combined perfusion/diffusion study [102] found abnormal appearing white
matter, described as leukoencephalopathy as well as SCI, had decreased CBF and also
decreased FA.
6. Cognitive outcome and relationship to brain imaging findings
Chronic disease (e.g. conditions secondary to anaemia such as diminished pulmonary function
and chronic hypoxic damage resulting in brain damage), potentially accumulating over time
[107], could explain compromised cognitive functioning in children with SCD [41]. Recurrent
micro‐infarctions of the central nervous system, possibly undetected by screening measures,
may affect general neuropsychological function [108].
6.1. General intelligence
Full‐scale intelligence quotient (IQ) is the most commonly reported and widely studied
standardised measure of general cognitive ability in SCD. Chodorkoff and Whitten [2] (1963)
published the first study investigating IQ between patients with SCD and controls—finding
no differences; however from the 1980s/early 1990s there were many studies suggesting that
patients have lowered global intelligence scores than matched controls, even when excluding
those with history of stroke or abnormal neurological examination [109–114]. Results from
studies at that time were mixed; some reported no differences in full‐scale IQ (FSIQ) between
patients and controls [115–117], whereas others found patients had lowered intelligence scores
than matched controls [109–112].
Figure 8. Forest plots of mean differences between SCD patients categorised by MRI status: stroke, silent cerebral in‐
farct (SCI+), no evidence of SCI (SCI−) and healthy controls. Mean differences (estimates) were significant between pa‐
tients with history of stroke vs. SCI+ (left panel), SCI+ vs. SCI− (middle panel) and SCI− vs. HC (right panel). CI:
confidence interval [3].
With the routine use of MRI added in the mid‐1990s, patients were classed into groups based
on history of stroke and presence or absence of SCI [42]; since then, several studies have
confirmed that children with SCI generally have lower IQ scores than those without evi‐
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dence of SCI [86, 92, 118–121]. Recent meta‐analyses have found children with history of stroke
perform significantly worse than those with SCI by 10 IQ points, children with SCI perform
significantly worse than children with normal MRI by 5–6 IQ points [122] and children with
normal MRI perform significantly worse than healthy controls by approximately 7 IQ points
[8] (Figure 8).
6.1.1. SCI and IQ
Although children with normal MRI have lowered IQ than healthy controls, these findings
may link presence of SCI and size of SCI with IQ. Differences in T2‐weighted/FLAIR protocols
and lesion quantification methods have varied, and are difficult to interpret. Results are mixed;
where one study did not provide any correlation result with IQ [86], two studies found volume
of SCI to be a significant predictor of IQ [123, 124] and one study found only patients with
larger lesions had lower IQ [125].
6.2. Executive functioning
Due to the localisation of SCI primarily in the frontal lobe white matter, much work has focused
on deficits in executive functioning, an umbrella term for frontal lobe functions such as
inhibition, planning, organisation, processing, decision‐making, mental flexibility and
working memory. A comprehensive systematic review published in 2007 [126] found that 11
out of 13 studies showed executive function and attention were impaired in children with SCD,
in domains such as sustained attention [127–129], cognitive flexibility [68, 130] and working
memory [64, 68, 123, 127, 131–133]. Some executive function deficits have been linked
specifically to the presence of frontal lobe lesions [127, 129, 134], including one cognitive
screening study finding the Test of Variables of Attention task was sensitive and specific in
identifying 86% of children with SCI [135]. Patients with no evidence of SCI were found to
have deficits in visuomotor functions compared to siblings [127, 129], whereas other studies
found no differences in sustained visual attention [92], working memory [123] or set‐shifting
[68]. A study of neurologically intact adults with SCD showed deficits in processing speed,
working memory and other executive functions compared to controls [136].
6.3. Non-imaging biomarkers of function
Anaemia is a major mediator of cognitive function in neurologically intact children (i.e. without
cerebrovascular abnormalities). Anaemia severity has shown moderate to large correlations
with IQ [41, 119, 137, 138]. Severely anaemic patients (i.e. haematocrit <20%) have shown
poorer performance on both verbal and performance aspects of IQ [119], and have accounted
for a significant proportion of variance in FSIQ [64, 138] and executive functions [64].Low
nocturnal peripheral oxygen saturation was associated with reduced performance on the
Tower of London test, which measures strategic planning and rule learning [139]. In the
baseline data from the Silent Infarct Trial, a 1% reduction in daytime oxygen saturation was
associated with a reduction in 0.75 full scale IQ points [122].
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Anaemia and hypoxia may also interact with social/environmental factors such as socioeco‐
nomic status [140]. Large cohort studies have found socioeconomic status and parent education
as major predictors of cognitive function, rather than SCI [122, 141].
7. Impact of therapeutic interventions
Although primary stroke prevention with prophylactic blood transfusions is effective [45],
with post‐RCT epidemiological evidence for reduction in the number of strokes in children
with sickle cell disease [142, 143], treatment is expensive [144], the number needed to treat to
prevent one stroke is 7 and lifelong regular blood transfusion [145] is a heavy burden for the
child and the family, with risk of allo‐immunisation and infection. Regular blood transfusion
also prevents reinfarction in those with SCI, but the number needed to treat to prevent one
reinfarction was even higher; the outcomes for the SIT trial included overt strokes and it is not
clear whether this treatment can halt or reverse the progression of SCI while there was no
benefit in terms of IQ [61, 62]. Longer term clinical and imaging follow‐up is required as blood
transfusion does not prevent all recurrent infarcts, worsening vasculopathy [51] or progressive
atrophy [146].
Hydroxyurea does appear to reduce TCD velocities and the TWiTCH trial supports its use for
primary prevention in those with abnormal TCD velocities who have normal MRA and have
been transfused for a year. There is now a little observational evidence suggesting prevention
of progression of SCI [69] and intellectual decline [147] but RCTs are needed.
Daytime and nocturnal desaturation is associated with higher TCD velocities [39] as well as
predicting increased stroke risk [22, 23]. Hydroxyurea may reduce stroke risk by improving
oxygen saturation [148] and other strategies, e.g. to prevent the development of or to treat
obstructive sleep apnoea, are under investigation. The SIT trial was the first to use MRI as an
imaging endpoint; the new techniques such as volumetric analysis and DTI may be useful
intermediate endpoints in RCTs of complex interventions, such as the Prevention of morbidity
in Sickle Cell Disease (POMS) randomised trials of auto‐adjusting continuous positive airways
pressure [149, 150].
8. Conclusion
In SCD, neurological complications secondary to chronic anaemia and hypoxia are prevalent
from an early age. The research is mounting that stroke and SCI, as well as other pathologies,
can have marked impact on neuropsychological outcome of the child. In clinical settings, MRI
and MRA have been considered valuable tools for diagnosis and management of acute CNS
events, but only relatively recently the role of quantitative neuroimaging has emerged for
establishing potential biomarkers of SCD severity. Cross‐sectional studies using high‐resolu‐
tion 3D T1‐weighted images, diffusion tensor imaging and perfusion imaging have found
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pertinent tissue characteristics beyond the detection of conventional, clinical MRI/MRA. These
studies open the way for use of quantitative MRI as endpoints in clinical trials.
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